---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-24-000100"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:39:02.182657+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals posts record Q3 revenue of $148.3M, raises 2024 guidance

## Summary
- Record quarterly net revenue of $148.3M (+12.5% YoY); Cortrophin Gel revenue $52.6M (+76.8%).
- GAAP net loss of $24.2M (-$1.27 diluted EPS) vs net income of $9.5M year ago; adjusted non-GAAP EPS of $1.34.
- Completed Alimera acquisition on Sept 16, adding ILUVIEN and YUTIQ; contributed $3.9M revenue in partial quarter.
- Raised FY2024 guidance: net rev $594-602M, adjusted EBITDA $149-153M, adjusted EPS $4.90-$5.05.
- New capital structure with $316.25M 2.25% convertible notes due 2029; expected to reduce interest expense ~$39M annually.

## SEC filing metadata
- accession: 0001023024-24-000100
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000100/0001023024-24-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000100/ani-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-24-000100
- JSON: https://secwatch.observer/filing/0001023024-24-000100.json
- Plain text: https://secwatch.observer/filing/0001023024-24-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.